Tenaya Therapeutics (NASDAQ:TNYA) Stock Rating Lowered by Zacks Investment Research

Tenaya Therapeutics (NASDAQ:TNYA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company’s product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. “

NASDAQ TNYA opened at $10.00 on Thursday. Tenaya Therapeutics has a 12 month low of $9.25 and a 12 month high of $32.00. The company’s fifty day moving average is $19.61.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 10th. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.20). On average, equities research analysts predict that Tenaya Therapeutics will post -7.55 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $33,448,000. RA Capital Management L.P. bought a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $73,339,000. RTW Investments LP bought a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $48,581,000. Trustees of Columbia University in the City of New York bought a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $6,027,000. Finally, Caas Capital Management LP bought a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $1,033,000. Institutional investors own 86.19% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics Inc is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company’s product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc is based in SOUTH SAN FRANCISCO, Calif.

Further Reading: Bear Market

Get a free copy of the Zacks research report on Tenaya Therapeutics (TNYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.